Abstracts tagged "Rheumatoid Factor"

Abstract Number: 1504 • 2018 ACR/ARHP Annual Meeting
Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
Alistair Reid^1,2,3, Michael D Wiese⁴, Robert Metcalf⁵, Mihir D Wechalekar^6,7, Anita Lee^8,9, Catherine Hill^2,10,11, Cindy Hall⁸, Leah McWilliams⁵, Les Cleland⁸ and Susanna Proudman¹², ¹Rheumatology, Royal Adelaide Hospital, NORTH ADELAIDE, Australia, ²Medicine, The University of Adelaide, Adelaide, Australia, ³Medicine, University of Wollongong, Wollongong, Australia, ⁴School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia, ⁷Rheumatology, Flinders University, Adelaide, Australia, ⁸Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁹Rheumatology, University of Adelaide, Adelaide, Australia, ¹⁰The Queen Elizabeth Hospital, Adelaide, Australia, ¹¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹²Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia
Background/Purpose: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define “seropositive” rheumatoid arthritis (RA). Both predict disease course, development of extra-articular features and treatment outcomes.…
Abstract Number: 1858 • 2018 ACR/ARHP Annual Meeting
An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
Thierry Dervieux¹, Laura Martinez Prat², John Conklin¹, Claudia Ibarra¹, Michael Mahler², Michael E Weinblatt³ and Joel Kremer⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-citrullinated peptide antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) but lack sensitivity. We evaluated autoantibodies to protein-arginine deiminase 4 (anti-PAD4) in distinguishing…
Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting
Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
Xinyi Liu¹, Cianna Leatherwood¹, Sara K. Tedeschi¹, Medha Barbhaiya², Cameron Speyer¹, Bing Lu³, Karen Costenbader¹, Elizabeth Karlson¹ and Jeffrey A. Sparks¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…
Abstract Number: 2046 • 2018 ACR/ARHP Annual Meeting
Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies
Mandar Bawadekar¹, Zihao Zheng², Alan J. Bridges^3,4, Michael A. Newton⁵ and Miriam A. Shelef^1,4, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ²Departments of Statistics, University of Wisconsin - Madison, Madison, WI, ³Medicine, University of Wisconsin - Madison, Madison, WI, ⁴William S. Middleton Memorial Veterans Hospital, Madison, WI, ⁵Departments of Statistics and of Biostatistics and Medical Informatics, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Rheumatoid arthritis patients produce a variety of anti-citrullinated protein antibodies (ACPAs) as well as antibodies that bind homocitrullinated and malondialdehyde-acetaldehyde adducted proteins leading to…
Abstract Number: 2051 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis
Jing Jing Wang¹, William Murray-Brown², Alexander Colella¹, Malcolm D. Smith³, Tim Chataway⁴, Jenny Walker², William H. Robinson⁵, Mihir D Wechalekar² and Tom Gordon^1,6, ¹Immunology, Flinders University, Adelaide, Australia, ²Rheumatology, Flinders University, Adelaide, Australia, ³Rheumotology, Flinders University, Adelaide, Australia, ⁴Proteomic Facility, Flinders University, Adelaide, Australia, ⁵Stanford University, Palo Alto, CA, ⁶Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Rheumatoid factors (RFs) are associated with disease activity and joint damage in rheumatoid arthritis (RA) and thought to play a pathogenic role in disease.…
Abstract Number: 2054 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², Gerard Collée³, L.R. Lard⁴, Tom W.J. Huizinga⁵, Cornelia F. Allaart⁶, René E.M. Toes⁵ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Rheumatology, Haaglanden Medical Center Antoniushove, Leidschendam, Netherlands, ⁴Rheumatology, LUMC, Leiden, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, LUMC, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies like rheumatoid factor (RF), anti-cyclic citrullinated peptide-2 (anti-CCP2), & anti-carbamylated protein (anti-CarP) antibodies. It…
Abstract Number: 43 • 2018 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
Jie An¹, Bhanupriya Madarampalli², Xizhang Sun², Lena Tanaka³, Erika H. Noss², Joshua Woodward⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶University of Washington, Seattle, WA
Background/Purpose: Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease affecting ~1% of the world population and can lead to permanent joint damage and severe…
Abstract Number: 2983 • 2018 ACR/ARHP Annual Meeting
The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study
Nathalie Carrier¹, Sophie Roux², Ariel Masetto², Artur J deBrum Fernandes³, Patrick Liang⁴, Meryem Maoui⁵ and Gilles Boire⁴, ¹Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Bristol-Myers Squibb Canada., St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution of baseline demographic, clinical, serological and genetic characteristics of patients with incident RA over 20 years. Methods: Since July 1998,…
Abstract Number: 87 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients with Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
Onno J. Arntz¹, Bartijn C.H. Pieters¹, Rogier Thurlings², Peter M. van der Kraan¹ and Fons A.J. van de Loo¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose:: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects synovial joints. Most research on RA has focused on cytokines as main effectors…
Abstract Number: 211 • 2018 ACR/ARHP Annual Meeting
Excess in Prevalence of Functional Disability in Patients with Rheumatoid Arthritis: Does Serologic Status Matter?
Elena Myasoedova¹, John M. Davis III¹, Sara J. Achenbach², Eric L. Matteson¹ and Cynthia S. Crowson², ¹Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Despite the advances in treatment of rheumatoid arthritis (RA) over the recent decades, many patients with RA do not achieve remission or full physical…
Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting
Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease
Annette de Thurah^1,2, Ina Trolle Andersen³, Andreas Bugge Tingaard⁴, Josephine Therkildsen⁵, Anders Hammerich Riis³, Morten Böttcher⁵ and Ellen-Margrethe Hauge^6,7, ¹Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁵Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
Abstract Number: 568 • 2018 ACR/ARHP Annual Meeting
Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial
Renaud Felten¹, Marie-Alexandra Alyanakian², Lucienne Chatenoud², Jean Sibilia¹, Frédérique Gandjbakhch³, Cédric Lukas⁴ and Jacques-Eric Gottenberg¹, ¹University Hospital of Strasbourg, Department of Rheumatology, Strasbourg, France, ²Laboratoire d'Immunologie Biologique, Hôpital Necker-Enfants Malades, Paris, France, ³Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France, ⁴University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), little is known about the prognostic relevance of the change in autoantibody (ab) levels. Seroconversion was reported to be associated…
Abstract Number: 1452 • 2018 ACR/ARHP Annual Meeting
Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis
Shinya Kawashiri¹, Keita Fujikawa², Ayako Nishino¹, Ayuko Takatani¹, Toshimasa Shimizu¹, Masataka Umeda¹, Shoichi Fukui¹, Takashi Igawa¹, Tomohiro Koga¹, Naoki Iwamoto¹, Kunihiro Ichinose¹, Mami Tamai¹, Hideki Nakamura¹, Tomoki Origuchi³ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: We conducted this retrospective study to determine objective and comprehensive diagnostic criteria for early rheumatoid arthritis (RA) that are based on ultrasound (US) and…
Abstract Number: 1470 • 2018 ACR/ARHP Annual Meeting
Russell Bodies and Serological Status in Rheumatoid Arthritis
Michael A. McNamara¹, Susan M. Goodman², Laura T. Donlin³, Dana Orange⁴, Serene Z. Mirza¹, Jackie Szymonifka², Mark P. Figgie⁵, Vivian P. Bykerk² and Edward F. DiCarlo⁶, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁴Rockefeller University, New York, NY, ⁵Surgery, Hospital for Special Surgery, New York, NY, ⁶Laboratory Medicine, Hospital for Special Surgery, New York, NY
Russell Bodies and Serological Status in Rheumatoid Arthritis Background/Purpose: Russell bodies (RBs) are globular aggregates of immunoglobulin produced by plasma cells and identified both within…
Abstract Number: 1473 • 2018 ACR/ARHP Annual Meeting
Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis
Peter M. Maloley¹, Bryant R. England², Harlan Sayles¹, Geoffrey M. Thiele¹, Michael J. Duryee³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cytokines and chemokines (CK) are central to RA pathogenesis, a fact underscored by the emergence of multiplex immunoassays for quantifying CK values in both…

« Previous Page
1
…
4
5
6
7
8
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].